Overview

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Status:
Enrolling by invitation

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is: • To evaluate the long-term safety of fostamatinib The secondary objectives are: - To compare the proportion of subjects with wAIHA who achieve a durable hemoglobin response - To estimate the durability of response in subjects receiving fostamatinib for wAIHA To assess steroid use in subjects with wAIHA treated with fostamatinib.

Phase:

Phase 3

Details

Lead Sponsor:

Rigel Pharmaceuticals

Treatments:

Antibodies
Autoantibodies
Immunoglobulins